Ivarmacitinib NCT07550452 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 18 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Not Applicable

Clinical phase

Not yet recruiting

Recruitment status

300

Planned enrollment

2027-06-30

Primary-completion proxy

Executive view

NCT07550452 evaluates Ivarmacitinib in Dermatitis, Atopic. The disclosed sponsor is Peking University People's Hospital, the design is Interventional, and the geographic footprint is Geography not reported. The first listed primary endpoint is Eczema Area and Severity Index (EASI 75) at Week 16, assessed over 16 Weeks.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07550452 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Dermatitis, Atopic landscape. Drug & Asset MCP drug_fetch was queried for Ivarmacitinib, while Company & Deal Intelligence MCP organization_fetch was queried for Peking University People's Hospital.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT07550452	Ivarmacitinib	Not Applicable / Not yet recruiting	Peking University People's Hospital	Geography not reported	Eczema Area and Severity Index (EASI 75) at Week 16 16 Weeks	2027-06-30
NCT07560618	Roflumilast	Phase 4 / Recruiting	Integrative Skin Science and Research	United States	Number of descriptors (besides itch) used to describe skin sensations associated with AD From enrollment to end of treatment at 4 weeks.	2027-08-01
NCT07558668	SYX-5219	Phase 1 / Recruiting	Sitryx Therapeutics Ltd.	United States, Ireland, Denmark, United Kingdom, Bulgaria, Germany	The Proportion of Participants With Treatment-Emergent Adverse Events Adverse events are collected from the date of consent until up to 10…	2026-08-30
CTRI/2026/04/109774	Tofacitinib Citrate	Phase 4 / Not Yet Recruiting	Sponsor not reported	India		Timing not reported
NCT07549750	HXN-5003	Phase 1 / Not yet recruiting	Helixon Biotechnology (Suzhou) Co., Ltd	Australia	Safety and tolerability of HXN5003 in healthy participants following single dose Baseline to Day 197	2027-03-18

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT07550452 is a Not Applicable, not yet recruiting study with 300 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.

The primary endpoint is “Eczema Area and Severity Index (EASI 75) at Week 16” over “16 Weeks.” The retrieved endpoint description is: Proportion of subjects achieving at least a 75% improvement in Eczema Area and Severity Index (EASI 75) from baseline at Week 16.

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 300 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

5 recent result records were selected as contextual evidence for Dermatitis, Atopic. These records do not establish direct evidence for NCT07550452 unless the registration number matches.

Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis

Phase 3; n=not reported; DLQI = 3.5 Point Source: https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/42165315/

Benefit–risk profile comparison between dupilumab and upadacitinib: a structured benefit–risk assessment of the Heads Up trial

Phase 3; n=385; Benefit-risk score = 61.0 point ; Benefit-risk score = 66.0 point Source: https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/42223292/

A Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of OpSCF in the Treatment of Adult Subjects With Moderate to Severe Atopic Derma…

Phase 2; n=50; Percent Change From Baseline in Eczema Area and Severity Index (EASI) at Week 16(Least Squares Mean): Least Square (LS) Mean Difference = -20.484(90% CI, -40.6573 to -0.3103), P-Value = 0.095; Percent Change From Baseline in Eczema Area and Severity Index (EASI) at Week 16(Least Squares Mean): Least Square (LS) Mean Difference = -20.484(90% CI, -40.6573 to -0.3103), P-Value = 0.095 Source: https://clinicaltrials.gov/ct2/show/results/NCT06101823

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

Ivarmacitinib is indexed as Small molecule drug with JAK1 biology and a global stage of Approved. The asset profile lists Jiangsu Hengrui Pharmaceuticals Co., Ltd. as an originator or developer.

Peking University People's Hospital is indexed in China. The organization record is used to resolve sponsor identity. The record lists an unreported number of development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Ivarmacitinib is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT07550452
Protocol source: https://clinicaltrials.gov/study/NCT07550452
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 18 September 2026.

Ivarmacitinib in Dermatitis, Atopic is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Eczema Area and Severity Index (EASI 75) at Week 16 and 2027-06-30 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP